Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation

Read full text Summarise with VIRAT
Authors: Jun-Feng Shi, Hui Xu, Jin-Feng Gao, Jianbin Wu
Cited by: 0
References: 31

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND The S-1+oxaliplatin (SOX) regimen shows limited efficacy in postoperative recurrent/metastatic gastric cancer (RMGC) treatment, requiring adjuvant therapy optimization to enhance effectiveness. AIM To clarify how adjuvant irinotecan-apatinib therapy works in postsurgical RMGC management using real-world data. METHODS We enrolled 124 postoperative RMGC cases (April 2021 to April 2024) and allocated them to the control (n = 60, sole irinotecan) and research (n = 64, irinotecan + apatinib) groups. All participants received intravenous S-1 infusion and oral oxaliplatin administration. Between-group comparisons were made regarding effectiveness, inflammation-associated parameters [vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, MMP-9], serum tumor biomarkers [carbohydrate antigen (CA) 242, CA199, carcinoembryonic antigen], and treatment-emergent adverse events (thrombocytopenia, hemoglobin reduction, nausea/vomiting, myelosuppression). Assessments were further extended to survival and life quality outcomes Generic Quality of Life Inventory-74 (GQOLI-74). RESULTS The between-group comparison revealed similar effectiveness, overall complications, and survival outcomes. The research group demonstrated greater post-treatment reductions in inflammatory markers and serum tumor biomarkers and achieved higher scores across all GQOLI-74 dimensions. CONCLUSION In real-world postoperative RMGC management, irinotecan-apatinib therapy achieves non-inferior antitumor efficacy, tolerability, and survival relative to irinotecan and more effectively attenuates inflammation, reduces serum tumor biomarkers, and improves quality of life.

Fields of Study & Subjects

Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies Intraperitoneal and Appendiceal Malignancies

Publication details

Journal / source
World Journal of Gastrointestinal Surgery
Volume
18
Issue
3
Publication date
26 March 2026
Language
EN